Evidence map›Paper›PMID 35289861›Full record

ArticleJAMA network open2022

Risk Factors Associated With Mortality and Neurologic Disability After Intracerebral Hemorrhage in a Racially and Ethnically Diverse Cohort.

Daniel Woo, Mary E Comeau, Simone Uniken Venema, Christopher D Anderson, Matthew Flaherty, Fernando Testai, Steven Kittner, Michael Frankel, Michael L James, Gene Sung and 21 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Early neurological improvement with deferoxamine after intracerebral hemorrhage: A post hoc analysis of the i-DEF trial.International journal of stroke : official journal of the International Stroke Society · 2025
    Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 18 institutions in 1 country.

Daniel WooDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Mary E ComeauDepartment of Biostatistics and Data Science, Center for Precision Medicine, Wake Forest University, Winston-Salem, North Carolina.
Simone Uniken VenemaCenter for Genomic Medicine, Massachusetts General Hospital, Boston.
Christopher D AndersonCenter for Genomic Medicine, Massachusetts General Hospital, Boston.
Matthew FlahertyDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Fernando TestaiDepartment of Neurology and Rehabilitation Medicine, University of Illinois College of Medicine, Chicago.
Steven KittnerDepartment of Neurology, Baltimore Veterans Administration Medical Center, University of Maryland School of Medicine, Baltimore.
Michael FrankelDepartment of Neurology, Emory University, Grady Memorial Hospital, Atlanta, Georgia.
Michael L JamesDepartments of Anesthesiology and Neurology, Duke University, Durham, North Carolina.
Gene SungNeurocritical Care and Stroke Division, University of Southern California, Los Angeles.
Mitchell ElkindDepartment of Neurology, Columbia University, New York, New York.
Bradford WorrallDepartment of Neurology, University of Virginia, Charlottesville.
Chelsea KidwellDepartment of Neurology, University of Arizona, Tucson.
Nicole GonzalesUniversity of Colorado Anschutz Medical Campus, Aurora.
Sebastian KochDepartment of Neurology, University of Miami, Miller School of Medicine, Miami, Florida.
Christiana HallDepartment of Neurology and Neurotherapeutics, UT-Southwestern, Dallas, Texas.
Lee BirnbaumDepartment of Neurology, University of Texas at San Antonio, San Antonio.
Douglas MaysonDepartment of Neurology, Medstar Georgetown University Hospital, Washington, District of Columbia.
Bruce CoullDepartment of Neurology, University of Arizona, Tucson.
Marc MalkoffDepartment of Neurology and Neurosurgery, University of Tennessee Health Sciences, Memphis.
Kevin N ShethDepartment of Neurology, Yale University, New Haven, Connecticut.
Jacob L McCauleyJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida.
Jennifer OsborneDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Misty MorganDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Lee GilkersonDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Tyler BehymerDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Elisheva R ColemanDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Jonathan RosandCenter for Genomic Medicine, Massachusetts General Hospital, Boston.
Padmini SekarDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Charles J MoomawDepartment of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Carl D LangefeldDepartment of Biostatistics and Data Science, Center for Precision Medicine, Wake Forest University, Winston-Salem, North Carolina.
University of Cincinnati Medical Center · USMassachusetts General Hospital · USUniversity of Arizona · USUniversity of Miami · USWake Forest University · USColumbia University · USDuke University · USGrady Memorial Hospital · USIllinois College · USMedStar Georgetown University Hospital · USThe University of Texas at San Antonio · USThe University of Texas Southwestern Medical Center · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Maryland, Baltimore · USUniversity of Southern California · USUniversity of Tennessee Health Science Center · USUniversity of Virginia · USYale University · US

Funding

Ethnic/Racial Variation in Intracerebral Hemorrhage (ERICH)U01NS069763 · NINDS · UNIVERSITY OF CINCINNATI · PI ANDERSON, CHRISTOPHER DAVID, DEMEL, STACIE · 2010 to 2024
$34.2M
NSTN National Clinical Coordinating CenterU01NS086872 · NINDS · UNIVERSITY OF CINCINNATI · PI Joseph Paul Broderick, Pooja Khatri · 2013 to 2026
$32.3M
Recurrent Hemorrhagic Stroke in Minority PopulationsR01NS093870 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI JONATHAN ROSAND, Amytis Towfighi · 2016 to 2026
$12.3M
Genetic and Environmental Risk Factors for Hemorrhagic StrokeU01NS036695 · NINDS · UNIVERSITY OF CINCINNATI · PI ROSAND, JONATHAN, WOO, DANIEL · 2016 to 2020
$7.0M
Cerebrovascular Fellowship Training ProgramT32NS047996 · NINDS · UNIVERSITY OF CINCINNATI · PI Joseph Paul Broderick, Stacie Demel · 2006 to 2026
$3.7M
NINDS NIH HHS R01 NS093870NINDS NIH HHS T32 NS047996NINDS NIH HHS U01 NS036695NINDS NIH HHS U01 NS069763NINDS NIH HHS U01 NS086872
6 · The paper itself

Abstract

Introduction: Intracerebral hemorrhage (ICH) is the most severe subtype of stroke. Its mortality rate is high, and most survivors experience significant disability. Objective: To assess primary patient risk factors associated with mortality and neurologic disability 3 months after ICH in a large, racially and ethnically balanced cohort. Design, Setting, and Participants: This cohort study included participants from the Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study, which prospectively recruited 1000 non-Hispanic White, 1000 non-Hispanic Black, and 1000 Hispanic patients with spontaneous ICH to study the epidemiological characteristics and genomics associated with ICH. Participants included those with uniform data collection and phenotype definitions, centralized neuroimaging review, and telephone follow-up at 3 months. Analyses were completed in November 2021. Exposures: Patient demographic and clinical characteristics as well as hospital event and imaging variables were examined, with characteristics meeting P < .20 considered candidates for a multivariate model. Elements included in the ICH score were specifically analyzed. Main Outcomes and Measures: Individual characteristics were screened for association with 3-month outcome of neurologic disability or mortality, as assessed by a modified Rankin Scale (mRS) score of 4 or greater vs 3 or less under a logistic regression model. A total of 25 characteristics were tested in the final model, which minimized the Akaike information criterion. Analyses were repeated removing individuals who had withdrawal of care. Results: A total of 2568 patients (mean [SD] age, 62.4 [14.7] years; 1069 [41.6%] women and 1499 [58.4%] men) had a 3-month outcome determination available, including death. The final logistic model had a significantly higher area under the receiver operating characteristics curve (C = 0.88) compared with ICH score alone (C = 0.76; P < .001). Among characteristics associated with neurologic disability and mortality were larger log ICH volume (OR, 2.74; 95% CI, 2.36-3.19; P < .001), older age (OR per 1-year increase, 1.04; 95% CI, 1.02-1.05; P < .001), pre-ICH mRS score (OR, 1.62; 95% CI, 1.41-1.87; P < .001), lobar location (OR, 0.22; 95% CI, 0.16-0.30; P < .001), and presence of infection (OR, 1.85; 95% CI, 1.42-2.41; P < .001). Conclusions and Relevance: The findings of this cohort study validate ICH score elements and suggest additional baseline and interim patient characteristics were associated with variation in 3-month outcome.

Indexed as

Cerebral HemorrhageStrokeCohort StudiesFemaleHumansRacial GroupsRisk Factors

Identifiers

PMID35289861
PMCPMC8924717
OpenAlexW4220665949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.